Vaccine and Infectious Disease Division
Join us Thursday, January 25 to learn why animals have an impact on immunocompromised patients, and new initiatives in antibiotic stewardship.
Investigating emerging infectious diseases to develop new diagnostic methods and clinical trials in immunocompromised individuals
Providing comprehensive approaches for antibiotic use, screening, isolation and prevention of healthcare-associated and drug-resistant pathogens within patient populations.
The IDS faculty have a wide range of expertise and diverse clinical and research backgrounds, many of whom have joint appointments with the University of Washington School of Medicine and the Seattle Cancer Care Alliance (SCCA) where they contribute to teaching, training, patient care and research missions.
Our physicians and scientists apply their extensive experience in immunocompetent and immunocompromised populations to study the epidemiology of infectious diseases, investigate emerging infectious diseases, develop novel diagnostic methods, and perform clinical trials for new treatments for major infections.
ID board-certifiied and world class physicians and scientists work closely together to deliver the most up to date options for diagnosis, treatment and prevention in cancer patients and immunocompromised hosts. They also direct the SCCA's nationally recognized Infection Prevention and Control and Antimicrobial Stewardship programs.
Our training programs in infectious diseases help to steer trainees to a path of academic and professional success. The Joel Meyers Endowment Scholarship and the T32 training grant provide critical support to young physician scientists who are on the cusp of launching their independence after devoting years of their lives to training in infectious diseases.